ADE and hyperinflammation in SARS-CoV2 infection- comparison with dengue hemorrhagic fever and feline infectious peritonitis

Cloutier, Maryse; Nandi, Madhumita; Ihsan, Awais Ullah; Chamard, Hugues Allard; Ilangumaran, Subburaj; Ramanathan, Sheela

doi:10.1016/j.cyto.2020.155256

Cited by 31 publications

(34 citation statements)

References 153 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is a concern that immune responses elicited by the SARS-CoV-2 vaccine could cause a disease-promoting effect, such as antibody-mediated antibody-dependent enhancement (ADE) or T helper 2 (Th2)-type mediated immunopathology (30). For example, studies on feline coronaviruses have shown that nonneutralizing coronavirus antibodies may cause ADE in feline infectious peritonitis (31). Meanwhile, T helper 2 (Th2)-type immunity induced by SARS-CoV nucleocapsid (N) protein could sometimes cause lung tissue immunopathology due to eosinophil infiltration (32).…”

Section: Discussionmentioning

confidence: 99%

A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation

et al. 2021

View full text Add to dashboard Cite

A coronavirus SARS-CoV-2, which has caused the pandemic viral pneumonia disease COVID-19, significantly threatens global public health, highlighting the need to develop effective and safe vaccines against its infection. In this study, we developed a novel DNA vaccine candidate against SARS-CoV-2 by expressing a chimeric protein of its receptor-binding domain (RBD) fused to a 33-bp sequence (11 aa) from the hepatitis B virus (HBV) preS1 region with a W4P mutation (W4P-RBD) at the N-terminal region and evaluated its immunogenicity. In vitro transfection experiments in multiple cell lines demonstrated that W4P-RBD vs. wild-type RBD protein (W-RBD) led to enhanced production of IL-6 and TNFα at the transcription and translation levels, suggesting the adjuvant potential of N-terminal HBV preS1 sequences for DNA vaccines against SARS-CoV-2. W4P-RBD also led to enhanced production of IgG and IgA, which can neutralize and block SARS-CoV-2 infection in both blood sera and bronchoalveolar lavage (BAL) fluid from the lung in vaccinated mice. Additionally, W4P-RBD led to an enhanced T-cell-mediated cellular immune response under S1 protein stimulation. In summary, W4P-RBD led to robust humoral and cell-mediated immune responses against SARS-CoV-2 in vaccinated mice, highlighting its feasibility as a novel DNA vaccine to protect against SARS-CoV-2 infection.

show abstract

Section: Discussionmentioning

confidence: 99%

A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Some authors argue that the possibility of ADE would have therapeutic implications that should be addressed urgently, in particular with vaccines, hyperimmune globulin and convalescent plasma (128,129). Others have speculated on the possible relationship between ADE and severity in COVID-19 patients (122,130), while some have even suggested that ADE is responsible for specific conditions such as multisystem inflammatory syndrome in children or hyperinflammation in people living with COVID-19 (131,132). In addition, the potential role of ADE has been suggested in the Nevada reinfection case, but aside from speculation, there is no evidence or support for this hypothesis (90).…”

Section: Neutralizing Antibody Response: Importance and Considerations On Its Effectmentioning

confidence: 99%

Antibody Responses in COVID-19: A Review

et al. 2021

View full text Add to dashboard Cite

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread worldwide as a severe pandemic. Although its seroprevalence is highly variable among territories, it has been reported at around 10%, but higher in health workers. Evidence regarding cross-neutralizing response between SARS-CoV and SARS-CoV-2 is still controversial. However, other previous coronaviruses may interfere with SARS-CoV-2 infection, since they are phylogenetically related and share the same target receptor. Further, the seroconversion of IgM and IgG occurs at around 12 days post onset of symptoms and most patients have neutralizing titers on days 14-20, with great titer variability. Neutralizing antibodies correlate positively with age, male sex, and severity of the disease. Moreover, the use of convalescent plasma has shown controversial results in terms of safety and efficacy, and due to the variable immune response among individuals, measuring antibody titers before transfusion is mostly required. Similarly, cellular immunity seems to be crucial in the resolution of the infection, as SARS-CoV-2-specific CD4+ and CD8+ T cells circulate to some extent in recovered patients. Of note, the duration of the antibody response has not been well established yet.

show abstract

“…Cytokine storm is a hyperinflammatory, pathological state that results from a sudden increase in certain circulating pro-inflammatory cytokine levels, which leads to overwhelming systemic inflammation, exacerbating viral pathogenesis and causing sepsis, ARDS, and multi-organ failure [7] , [8] , [9] , [10] , [11] . The cytokine storm has also been observed in SARS, MERS, H5N1 influenza, and H7N9 influenza, and with other respiratory viruses [12] .…”

Section: Pathogenesis Of Sars-cov-2 Infectionmentioning

confidence: 99%

Cytokine storm induced by SARS-CoV-2 infection: The spectrum of its neurological manifestations

et al. 2021

View full text Add to dashboard Cite

ADE and hyperinflammation in SARS-CoV2 infection- comparison with dengue hemorrhagic fever and feline infectious peritonitis

Abstract: Highlights ADE increases viraemia in DHF and in FCoV infections. In SARS-CoV infections ADE promotes inflammation. The underlying cause of hyperinflammation is not clear in Covid-19.

Cited by 31 publications

References 153 publications

A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation

A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation

Antibody Responses in COVID-19: A Review

Cytokine storm induced by SARS-CoV-2 infection: The spectrum of its neurological manifestations

Contact Info

Product

Resources

About